Sorry, but the browser version you are currently using is not supported by this website. We recommend that you update or download a more recent version.

NEWS

We innovate

healthcare solutions

by embedding connectivity in therapeutics
and medical intelligence in software

With excellence and innovation at heart,

Voluntis designs
state-of-the-art solutions

for chronic and rare diseases to empower patients by embedding intelligence in mobile phones and to simplify care provision by powering health data management.

ABOUT US


Voluntis was founded in 2001 by three entrepreneurs who believed that innovative medical solutions built with advanced information technologies would transform patient lives, enhance medical practices and quality of care by improving medical real-life outcomes and thus increase healthcare system efficiency.

Every day, Voluntis teams seek to invent secure, collaborative and patient-centric digital health solutions with a unique combination of web and mobile development excellence, medical and regulatory expertise and certified quality-orientated processes. With more than 600,000 patients managed and more than 50 programs deployed, our track-record speaks for itself.

  • 600.000
    patients managed
  • 50
    programs deployed

At Voluntis, we are all guided by clear and simple values:

  • We are focused on patients: we are committed to change the daily lives of patients by addressing their unmet needs and by empowering them to manage their chronic condition.
  • We are passionate about innovation: we design next-generation solutions that combine digital and medical expertise to solve the daily problems of patients and care givers.
  • We work with respect and integrity: everyday, we take care of the people we touch, our patients, customers, partners and employees.
  • We are driven by excellence: in everything we do, we behave ethically and we strive to attain the highest level of quality. Always working to enhance our processes, Voluntis is certified ISO 9001, ISO 13485 and compliant with ISO 14971 standard. Our design methodologies embed the harmonized IEC 62304 and IEC 62366 standards.
  • Pierre LEURENT

    Chief Executive Officer, President of the Management Board and Founder

    Pierre LEURENT

  • Romain MARMOT

    Chief Operations Officer, Co-Founder and Member of the Management Board

    Romain MARMOT

  • Dominique LAUBIER

    Chief Financial
    Officer

    Dominique LAUBIER

  • Dr Geneviève D'ORSAY

    Chief Medical
    Officer

    Geneviève D'ORSAY, MD

  • Olivier BERROUIGUET

    Chief
    Commercial
    Officer

    Olivier BERROUIGUET

  • Alexandre CAPET

    Chief Strategy & Marketing Officer and Member of the Management Board

    Alexandre CAPET

  • Etienne VIAL

    Vice-President Innovation and Co-Founder.

    Etienne VIAL

  • Laurent DELORME

    Vice-President Consulting, Infrastructure & Support

    Laurent DELORME

  • Damien McKEON

    Vice-President Quality Assurance & Validation

    Damien McKEON

Bpifrance

Formed by the law of 31 December 2012, Bpifrance (a public sector investment bank) is the outcome of the merger between OSEO, the FSI, CDC Entreprises and FSI Régions. Its two shareholders are the French state and the Caisse des Dépôts bank. Its object is to support businesses (SMEs, medium-sized enterprises and larger companies of a strategic importance to the French economy), from start-up through to stock market flotation, by providing loans, guarantees and equity. Bpifrance also provides enhanced support and backing for innovation, export, and external growth. With its 42 regional offices, it is a one-stop shop for entrepreneurs in each region for all their finance and investment needs. www.bpifrance.fr - Follow us on Twitter: @bpifrance

Innovation Capital

Founded in 1996, Innovation Capital is an international venture capital firm based in Paris with a local presence in the Silicon Valley. With over €450 million under management, Innovation Capital current focus is on venture and growth investments in the Innovative Healthcare Services space in Europe. Innovation Capital aims to create value by providing talented entrepreneurs with the resources, experience, and network necessary to turn innovative technologies into great businesses.

Vesalius

Vesalius Biocapital is a pan-european venture capital group investing in early stage innovative biotech companies. Most of our investments consist of therapeutic companies, developing new drugs and devices. Our total fund size is €160 million. The team is composed of experienced life science experts and business people.

Qualcomm Incorporated

Qualcomm Incorporated is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated includes Qualcomm’s licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a wholly-owned subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of Qualcomm’s engineering, research and development functions, and substantially all of its products and services businesses, including its semiconductor business, QCT. For more than 25 years, Qualcomm ideas and inventions have driven the evolution of digital communications, linking people everywhere more closely to information, entertainment and each other. For more information, visit Qualcomm’s website, OnQ blog, Twitter and Facebook pages.

CM-CIC Capital Innovation

CM-CIC Capital Innovation specializes in venture capital tech investments. In addition to Sudinnova, it supports the development of companies with strong growth potential in dynamic sectors such as information technologies, healthcare, industrial innovation and the environment. CM-CIC Capital Innovation is a subsidiary of CM-CIC Capital Finance, the investment wing and merchant bank of the Crédit Mutuel-CIC Group. With €2.6 billion in capital (including €1.9 billion in equity), a portfolio of 630 companies, and 6 regional branches throughout France (Paris, Lyon, Nantes, Lille, Strasbourg and Bordeaux), CM-CIC Capital Finance is one of the few merchant banks that invests its own funds for the long term.

CapDecisif Management

CapDecisif Management manages CapDecisif, FCPR CapDecisif 3 and G1J Ile-De-France, early-stage venture capital funds sponsored by Bpifrance, the Ile-de-France region and BNP. Since 2002, the management team has invested in 32 new information technology companies in software, the life sciences, biotech, energy and the environment, and the engineering sciences. CapDecisif Management currently manages almost €100 million.

Sham

Created in 1927, Sham is a mutual insurance company specializing in risk management for healthcare, social and medico-social stakeholders. It is the leading insurer for medical legal liability in France, with an asset portfolio of €1.6 billion invested in various channels. Since 2007, the company has also been investing in innovative healthcare businesses.

OUR VISION

We firmly believe that the unprecedented advancement of information
technologies will contribute to solving certain healthcare system issues,
notably related to chronic diseases expansion.


  • QUANTIFIED SELF
  • Personalized
    medicine
  • remote medical
    pratice
  • collaborative
    interactions
  • innovative
    payer model
  • digital
    distribution chanel
  • integrated care
    delivery
  • patients
    empowerment
  • smartphone
    and tablet
    proliferation
  • data driven
    medicine
  • BIG
    DATA

Major mega-trends suggest that the digital healthcare
revolution is already bounding forward in leaps


At Voluntis, we believe these remarkable changes are the pivotal factors that are already transforming healthcare systems. We are poised and ready to catapult the best from advanced technologies towards improving healthcare.

Committed to this vision, Voluntis designs companion software to transform healthcare by :

  • designing integrated care services aligning interests of patients, providers and payers
  • driving cost downwards while improving quality
  • entering new collaborative schemes with stakeholders

OUR OFFER



COMPANION SOFTWARE

At Voluntis, we develop state-of-the-art companion software to accompany
and enhance a specific medication or medical device.

We design our companion software in a user-friendly manner with the ob-
jective of augmenting the real-life value of therapeutics by: 

Means, for instance, designing clinical algorithms that supports decision-making, such as a medication dosage.

Means, in particular, liaising securely patients with care givers in order to activate remote operations, such as monitoring, treatment adjustment or coaching.

Means, for instance, promoting data sharing between the doctor and the patient to foster engagement, and also enabling effective task delegation among healthcare professionals to optimize time.


Companion to an existing medication or medical device, companion software aims at monitoring side-effects, promoting adherence, recommending dosage or connecting patients with the healthcare team.

Regulatory wise, our companion software might be classified as software medical device according to prevailing regulation. To comply strictly with regulations, Voluntis has developed an extensive regulatory expertise and implemented high quality standards.

As such, companion software have the potential to empower patient, prevent complications and, ultimately, to augment the real-life value of a medication.

We can conduct clinical studies to demonstrate the value and medical benefits of our companion software. In the field diabetes m-health, our companion is one of the most extensively studied solution. In hemophilia, we have designed a companion software currently under clinical evaluation.

Voluntis develops proprietary companion software but also provides partners with development and regulatory capabilities to elaborate their own companion software.

A COMPANION SOFTWARE FOR

Diabeo® / Insulia®1 product information are specific to a particular country.
Please select the country or region in which you are located. By selecting a country or region, you acknowledge that the information displayed is for the residents of the selected country or region.

Diabeo® / Insulia®1 is a standalone software device that combines a mobile application for patients and a web interface for healthcare professionals.

Diabeo® / Insulia®1 is not approved for use in the U.S.A.

Diabeo® / Insulia®1 is a standalone software device that combines a mobile application for patients and a web interface for healthcare professionals.

Diabeo® / Insulia®1,
our insulin companion software

Diabeo® / Insulia®1 provides therapeutic and decision-making support for effective diabetes management, assuring :

  • to help adult patients titrate basal and bolus insulin,
  • to facilitate interactions between the patient and their healthcare professionals,
  • to support remote management and the implementation of telemedicine services.

Diabeo® / Insulia®1 suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on doses that are their own.


Diabeo® / Insulia®1 was conceived as part
of a significant clinical program :

  • 2013
  • 2008
  • 2007

Diabeo® / Insulia®1 is granted CE Mark

Diabeo® / Insulia®1 was granted CE Mark in December 2013.

 

1Diabeo® is a registered trade-mark of Sanofi. Insulia® is a registered trade-mark of Voluntis.

Diabeo® / Insulia®1 is a standalone software device that combines a mobile application for patients and a web interface for healthcare professionals.

Diabeo® / Insulia®1,
our insulin companion software

Diabeo® / Insulia®1 provides therapeutic and decision-making support for effective diabetes management, assuring :

  • to help adult patients titrate basal and bolus insulin,
  • to facilitate interactions between the patient and their healthcare professionals,
  • to support remote management and the implementation of telemedicine services.

Diabeo® / Insulia®1 suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on doses that are their own.


Diabeo® / Insulia®1 was conceived as part
of a significant clinical program :

  • 2013
  • 2008
  • 2007

Diabeo® / Insulia®1 is granted CE Mark

Diabeo® / Insulia®1 was granted CE Mark in December 2013.

 

1Diabeo® is a registered trade-mark of Sanofi. Insulia® is a registered trade-mark of Voluntis.

In the anticoagulation treatment, the compliance is crucial: the INR must be regularly measured to ensure the appropriate dosage of the vitamin K antagonist treatment.

In collaboration with Roche Diagnostics, Voluntis has developed a software companion to enhance the CoaguChek INR self-testing device.

This CoaguChek Link solution centralizes the INR data measured by patients, connects patients with the independent diagnostic testing facility and enables effective telemonitoring system by healthcare professionals.

Thus, CoaguChek Link simplifies care delivery, ensures compliance and enables doctors and patients stay connected to work together on managing the anticoagulant treatment.

In hemophilia, we work to help patients managing their condition. This innovative solution intends to simplify the remote monitoring of bleeding events as well as inventory medication management. This solution is currently under clinical evaluation.


Medpassport
platform

Foundation of our core system architecture, Medpassport is a cloud operated and modular webbased platform designed to manage proficiently health data by collecting, hosting and analyzing data, and by processing the communication flows through configurable roles and workflows.

CAREERS

Talented? Passionate about medical and digital?
Willing to help patients to live a normal life ?
You might just fit in...


CONTACT US

Voluntis is headquartered in Paris, France,
and has offices in Boston, USA.



Voluntis FRANCE

Tour Ventôse,
2 rue des Bourets
92150 Suresnes
FRANCE 00 331 41 38 39 20

info@voluntis.com

Voluntis USA

One Broadway
Cambridge, MA 02142
USA 00 1 301 346 77 95

info@voluntis.com

CREDITS

WEBSITE CREATION

POSSUM INTERACTIVE

88, bis rue de Buzenval
75020 PARIS
FRANCE
00 331 83 56 66 90

www.possum-interactive.com

PHOTOS CREDITS

iStockphoto © Geber86 - iStockphoto © bevangoldswain
iStockphoto © AleksandarNakic.